Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas

British Journal of Cancer

Volumn 74, Issue 2, 1996, Pages 216-223

  Smith, D R ^a,b   Ji, C Y ^a   Goh, H S ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Colon cancer; Tumour suppressor

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; COLORECTAL CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0030035991     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.340     Document Type: Article

References (65)

1. BAKER SJ, FEARON ER, NIGRO JM, HAMILTON SR, PREISINGER AC, JESSUP JM, VAN TUINEN P, LEDBETTER DH, BARKER DF, NAKAMURA Y, WHITE R AND VOGELSTEIN B. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science, 244, 217-220.
2. BAKER SJ, PREISINGER AC, JESSUP JM, PARASKEVA C, MARKOWITZ S, WILSON JKV, HAMILTON S AND VOGELSTEIN B. (1990). p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res., 50, 7717-7722.
3. BANKS L, MATIACHEWSKI G AND CRAWFORD L. (1989). Isolation of human-p53-specific monoclonal antibodies and their use in studies of human p53 expression. Eur. J. Biochem., 159, 529-534.
4. BEART RW, MELTON LJ, MARUTA M, DOCKERTY MB, FRYDENBERG HB AND O'FALLON WM. (1983). Trends in right- and left-sided colon cancer. Dis. Colon Rectum, 26, 393-398.
5. BELL SM, SCOTT N, CROSS D, SAGAR P, LEWIS FA, BLAIR GE, TAYLOR GR, DIXON MF AND QUIRKE P. (1993). Prognostic value of p53 over-expression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology, 104, 57-64.
6. BODNER SM, MINNA JD, JENSEN SM, D'AMICO D, CARBONE D, MITSUDOMI T, FEDORKO J, BUCHHAGEN DL, NAU MM, GAZDAR AF AND LINNOILA I. (1992). Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7, 743-749.
7. BOSARI S, VIALE G, BOSSI P, MAGGIONI M, COGGI G, MURRAY JJ AND LEE AKC. (1994). Cytoplasmic accumulation of p53 protein: an independent prognostic indicator of colorectal adenocarcinomas. J. Natl Cancer Inst., 86, 681-687.
8. CAMPO E, MIGUEL R, JARES P, BOSCH F, JUAN M, LEONE A, VIVES J, CARDESA A AND YAGUE J. (1994). Prognostic significance of the loss of Nm23-H1 and p53 genes in colorectal cancer. Cancer, 73, 2913-2921.
9. CHEN P, CHEN Y, BOOKSTEIN R AND LEE W. (1990). Genetic mechanisms of tumor suppression by the human p53 gene. Science, 250, 1576-1580.
10. COOK A AND MILNER J. (1990). Evidence for allosteric variants of wild type p53, a tumour suppressor protein. Br. J. Cancer, 61, 548-552.
11. CRIPPS K, PURDIE CA, CARDER PJ, KOMINE K, BIRD CC AND WYLLIE AH. (1994). A study of p53 protein versus point mutation in colorectal carcinoma. Oncogene, 9, 2739-2743.
12. DITTMER D, PATI S, ZAMBETTI G, CHU S, TERSKY AK, MOORE M, FINLAY C AND LEVINE AJ. (1993). Gain of function mutations in p53. Nature Genet., 4, 42-46.
13. DIX BR, ROBBINS P, SOONG R, JENNER D, HOUSE A AND THE GENERAL SURGEONS AT SIR CHARLES GAIRDNER HOSPITAL. (1994a). The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int. J. Cancer, 59, 747-751.
14. DIX B, ROBBINS P, CARRELLO S, HOUSE A AND IACOPETTA B. (1994b). Comparison of p53 gene mutation and protein over-expression in colorectal carcinomas. Br. J. Cancer, 70, 585-590.
15. DUKES CE. (1932). The classification of cancer of the rectum. J. Pathol. Bacteriol., 35, 323-332.
16. ELIYAHU D, MICHALOVITZ D, ELIYAHU S, PINHASHI-KIMHI O AND OREN M. (1989). Wild type p53 can inhibit oncogene mediated focus formation. Proc. Natl Acad. Sci. USA, 86, 8763-8767.
17. GANNON JV, GREAVES RV, IGGO R AND LANE DP. (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., 9, 1595-1602.
18. GOH H-S, CHAN C-S, KHINE K AND SMITH DR. (1992). p53 and behaviour of colorectal cancer. Lancet, 344, 233-234.
19. GOH H-S, YAO J AND SMITH DR. (1995). p53 point mutation and survival in colorectal cancer patients. Cancer Res., 55, 5217-5221.
20. GREENBLATT MS, BENNET WP, HOLLSTEIN M AND HARRIS CC. (1994). Mutations of the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
21. GRONOSTAJSKI RM, GOLDBERG AJ AND PARDEE AB. (1984). Energy requirement for degradation of tumour-associated protein p53. Mol. Cell. Biol., 3, 442-448.
22. HAMELIN R, LAURENT-PUIG P, OLSCHWANG S, JEGO N, ASSELAIN B, REMVIKOS Y, GIRODET J, SALMON RJ AND THOMAS G. (1994). Association of p53 mutations with short survival in colorectal cancer. Gastroenterology, 106, 42-48.
23. HINDS P, FINLAY C AND LEVINE AJ. (1989). Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol., 63, 739-746.
24. HINDS PW, FINLAY CA, QUARTIN RS, BAKER SJ, FEARON ER, VOGELSTEIN B AND LEVINE AJ. (1990). Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes. Cell Growth Differ., 1, 571-580.
25. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B AND HARRIS C. (1991). p53 mutations in human cancers. Science, 253, 49-53.
26. HSU S-M, RAINE L AND FANGER H. (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J. Histochem. Cytochem., 29, 577-580.
27. ISOBE M, EMANUEL BS, GIVOL D, OREN M AND CROCE C. (1986). Localisation of the gene for human p53 tumor antigen to band 17p13. Nature, 320, 84-85.
28. JENKINS JR, RUDGE K AND CURRIE GA. (1984). Cellular immortalisation by a cDNA clone encoding the transformation associated phosphoprotein p53. Nature, 312, 651-654.
29. KERN SE, FEARON ER, TERSMETTE KWF, ENTERLINE JP, LEPPERT M, NAKAMURA Y, WHITE R, VOGELSTEIN B AND HAMILTON SR. (1989). Allelic loss in colorectal caner. JAMA, 261, 3099-3103.
30. KHINE K, SMITH DR AND GOH HS. (1994). High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer. Cancer, 73, 28-35.
31. KHINE K, GOH H-S AND SMITH DR. (1995). Prognostic significance of chromosome 5q and 17p allelic deletion in colorectal adenocarcinomas. Int. J. Oncology, 7, 631-635.
32. LANE DP AND CRAWFORD L. (1979). T antigen is bound to a host protein in SV40 transformed cells. Nature, 278, 261-263.
33. LAURENT-PUIG P, OLSCHWANG S, DELATTRE O, REMVIKOS Y, ASSELAIN B, MELOT T, VALIDIRE Y, MULERIS M, GIRODET J, SALMON RJ AND THOMAS G. (1992). Survival and acquired genetic alterations in colorectal cancer. Gastroenterology, 102, 1136-1141.
34. LEVINE AJ, MOMAND J AND FINLAY CA. (1991). The p53 tumor suppressor gene. Nature, 351, 453-456.
35. LEVINE AJ, PECRY ME, CHANG A, SILVER A, DITTMER D, WU M AND WELSH D. (1994). The 1993 Walter Hubert Lecture: The role of the p53 tumour suppressor gene in tumorigenesis. Br. J. Cancer, 69, 409-416.
36. MCBRIDE OW, MERRY D AND GIVOL D. (1986). The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc. Natl Acad. Sci. USA, 83, 130-134.
37. MILNER J AND MEDCALF EA. (1991). Cotranslation of activated mutant p53 with wild type drives the wild type p53 protein into the mutant conformation. Cell, 65, 765-774.
38. MULDER J-WR, BAAS IO, POLAK MM, GOODMAN SN AND OFFERHAUS GJA. (1995). Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br. J. Cancer, 71, 1257-1262.
39. MULLIGAN LM, MATLASHEWSKI GJ, SCRABLE HJ AND CAVENEE WK. (1990). Mechanism of p53 loss in human sarcomas. Proc. Natl Acad. Sci. USA, 87, 5863-5867.
40. NATHANSON SD, LINDEN MD, TENDER P, ZARBO RJ, JACOBSON G AND NELSON LS. (1994). Relationship among p53, stage and prognosis of large bowel cancer. Dis. Colon Rectum, 37, 527-534.
41. NIGRO JM, BAKER SJ, PREISINGER AC, JESSUP JM, HOSTETTER R, CLEARY K, BIGNER SH, DAVIDSON N, BAYLIN S, DEVILEE P, GLOVER T, COLLINS FS, WESTON A, MODALI R, HARRIS CC AND VOGELSTEIN B. (1989). Mutations in the p53 gene occur in diverse human tumor types. Nature, 342, 705-708.
42. O'CONNELL MJ, SCHAID DJ, GANJU V, CUNNINGHAM J, KOVACH JJ AND THIBODEAU SN. (1992). Current status of adjuvant chemotherapy for colorectal cancer. Cancer, 70, 1732-1739.
43. OREN M, MALTZMAN W AND LEVINE AJ. (1981). Post translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol. Cell. Biol., 1, 101-110.
44. ORITA M, IWAHANA H, HAYASHI K AND SEKIYA T. (1989a). Detection of polymorphisms of human DNA by gel electrophoresis as single strand conformation polymorphisms. Proc. Natl Acad. Sci. USA, 86, 2766-2770.
45. ORITA M, SUZUKI Y, SEKIIYA T AND HAYASHI K. (1989b). Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5, 874-879.
46. ORY K, LEGROS Y, AUGUIN C AND SOUSSI T. (1994). Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J., 13, 3496-3504.
47. PARADA L, LAND H, WEINBERG R, WOLF D AND ROTTER V. (1984). Cooperation between gene encoding p53 tumor antigen and ras in cellular transformation. Nature, 312, 649-651.
48. REICH NC, OREN M AND LEVINE AJ. (1983). Two distinct mechanisms regulate the level of a cellular tumour antigen, p53. Mol. Cell. Biol., 3, 2143-2150.
49. REMVIKOS Y, TOMINAGA O, HAMMEL P, LAURENT-PUIG P, SALMON RJ, DUTRILLAUX B AND THOMAS G. (1992). Increased p53 protein content of colorectal tumours correlates with poor survival. Br. J. Cancer, 66, 758-764.
50. RODRIGUEZ NR, ROWAN A, SMITH MEF, KERR IB, BODMER WF, GANNON JV AND LANE DP. (1990). p53 mutations in colorectal cancer. Proc. Natl Acad. Sci. USA, 87, 7555-7559.
51. ROVINSKI B AND BENCHIMOL S. (1988). Immortilization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene, 2, 445-452.
52. SARNOW P, HO YS, WILLIAMS J AND LEVINE AJ. (1982). Adenovirus E1b-58 kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell, 28, 387-394.
53. SAKAI E AND TSUCHIDA N. (1992). Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene, 7, 927-933.
54. SCOTT N, SAGAR P, STEWART J, BLAIR GE, DIXON HF AND QUIRKE P. (1991). p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br. J. Cancer, 63, 317-319.
55. SMITH DR, CHAN C-S AND GOH H-S. (1994a). A detailed study of p53 mutations in colorectal cancer in Singapore. Ann. Acad. Med. Singapore, 23, 803-809.
56. SMITH DR, KHINE K, CHAN C-S AND GOH H-S. (1994b). Tumour suppressor genes in colorectal carcinomas: p53 activation is highly associated with allelic loss of chromosome 5q. Int. J. Oncology, 5, 539-546.
57. STARZYNSKA T, BROMLEY M, GHOSH A AND STERN PL. (1992). Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br. J. Cancer, 66, 558-562.
58. SUN X-F, CARSTENSEN JM, ZHANG H, STAL O, WINGREN S, HATSCHEK T AND NORDENSKJOLD B. (1992). Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet, 340, 1369-1373.
59. TAKAHASHI T, NAU MM, CHIBA I, BIRRER MJ, ROSENBERG RK, VINOCOUR M, LEVITT M, PASS H, GADZAR AF AND MINNA JD. (1989). p53: a frequent target for genetic abnormalities in lung cancer. Science, 246, 491-494.
60. TURNBULL JR, KYLE K, WATSON FR AND SPRATT J. (1967). Cancer of the colon: the influence of the no-touch isolation technic on survival rates. Ann. Surg., 166, 420-427.
61. VOGELSTEIN B AND KINZLER KW. (1992). p53 function and dysfunction. Cell, 70, 523-526.
62. WARNKE R AND LEVY R. (1980). Detection of T and B cell antigens with hybridoma monoclonal antibodies. A biotin avidin horse-radish peroxidase method. J. Histochem. Cytochem., 28, 771-774.
63. WYNFORD-THOMAS D. (1992). p53 in tumour pathology: can we trust immunocytochemistry? J. Pathol., 166, 329-330.
64. YAMAGUCHI A, KURAKA Y, FUSHIDA S, KANNO M, YONEMURA Y, MIWA K AND MIYAZAKI I. (1992). Expression of the p53 protein in colorectal cancer and its relationship to short term prognosis. Cancer, 70, 2778-2784.
65. YAMAGUCHI A, NAKAGAWARA G, KUROSAKA Y, NISHIMURA G, YONEMURA Y AND MIYAZAKI I. (1993). p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br. J. Cancer, 68, 399-402.